DEWIZ-GOLF
deWiz Golf’s Board, including co-founders Christian Bergh and Markus Westerberg, has announced that Jesper Kärrbrink has been appointed new Chairman of the Board. Kärrbrink brings extensive experience from company leadership roles, currently as chairman of Green Jade Games and previously as CEO of, among others, Svenska Spel, Eniro, Euroflorist, Mr. Green, and Östersunds-Posten.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211020005415/en/
“On behalf of my co-founder Markus and deWiz's board, it is with great pride that I announce that Jesper has been appointed deWiz's new chairman of the board,” said Christian Bergh, co-founder and COO of deWiz Golf. “After five years of development and research, this has been an exciting year with the launch of deWiz and the future is even more exciting with executives like Jesper helping us guide us towards our strategic vision to revolutionize golf and other sports using our world-class wearable technology. Jesper's global experience will be of great value as deWiz expands across golf-rich markets, including North America, Europe and Asia.”
Launched this summer, deWiz is based on revolutionary wearable technology that combines capturing high-precision data of a golfer's swing in real time and biometric feedback to increase a golfer's pace of learning and consistency.
“deWiz is the perfect example of how technology can help players improve their golf game - at all levels,” said Jesper Kärrbrink, new chairman of deWiz Golf. “Artificial intelligence, data collection and motion sensors have been used for a long time to help elite athletes improve their performance. And what's really fascinating about deWiz is how it delivers this high-tech approach at my level, as a dedicated amateur golfer, through a wearable device that helps me to improve my game anywhere, whether I'm on the course, on the range or practicing on my swing at home.”
Today, golfers in the EU, North America and South Korea can buy deWiz and the company plans to expand with new markets in 2022, including Japan, Australia and South Africa.
DEVELOPED BY EXPERTS, TESTED BY PROS: deWiz has been under development for more than five years and has attracted an impressive list of ambassadors, including Bryson DeChambeau, U.S. Open champion from 2020; Annika Sorenstam, 10-time major-champion; Vijay Singh, 3-time major-champion; Lydia Ko, 2-time major champion; 2016 Open-champion Henrik Stenson; 2019 Houston Open-champion Lanto Griffin; and 2-time world champion in long drive, Tim Burke. deWiz's user-friendly app and wearable technology tracks the exact position of a golfer's hands throughout the swing, providing a 3D analysis and delivers data showing Transition , Backswing Length , Wedge Distance and Tempo . These unique deWiz data points provide measurable values that any avid golfer, professional teacher or world-class player can use to effectively refine their swing. As a Swedish developed and produced product, deWiz is focused on its mission to help golfers around the world increase their enjoyment of the game through innovative technology that increases their pace of learning. At the moment, deWiz sells for $699 and is available in the U.S., Canada, Europe and South Korea (more markets are opening regularly - visit the site for the latest updates). Visit dewizgolf.com for more information on how to improve your swing faster or download the app to demonstrate its features via the Apple App Store or Google Play.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211020005415/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 12:31:00 CET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 00:49:00 CET | Press release
‒ Named Most Respected Public Semiconductor Company Achieving $100 Million to $500 Million in Annual Sales ‒ Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom